MiNK Therapeutics (INKT) Research & Development (2020 - 2026)
MiNK Therapeutics (INKT) posted Research & Development of $1.2 million for Q1 2026, down 20.43% sequentially from $1.5 million in Q4 2025, and down 4.58% YoY from $1.3 million in Q1 2025.
MiNK Therapeutics (INKT) Research & Development (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Research & Development for 7 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Research & Development fell 4.58% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 12.9% YoY) and the FY2025 annual result came in at $5.8 million, down 9.13% from the prior year.
- Research & Development retreated to $1.2 million in Q1 2026 per INKT's latest filing, from $1.5 million in the prior quarter.
- Over five years, Research & Development peaked at $6.1 million in Q3 2022 and troughed at $540638.0 in Q3 2024.
- A 5-year average of $3.1 million and a median of $2.5 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 84.23% in 2024, then surged 111.45% in 2025.
- Over 5 years, Research & Development stood at $5.8 million in 2022, then sank by 43.04% to $3.3 million in 2023, then slumped by 57.53% to $1.4 million in 2024, then climbed by 7.62% to $1.5 million in 2025, then fell by 20.43% to $1.2 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.2 million, $1.5 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | MiNK Therapeutics | 57.77 Mn | 57.77 Mn | - | 1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.89 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 1.41 Mn |
| Sep 30, 2024 | 540,638.00 |
| Jun 30, 2024 | 1.84 Mn |
| Mar 31, 2024 | 2.55 Mn |
| Dec 31, 2023 | 3.31 Mn |
| Sep 30, 2023 | 3.43 Mn |
| Jun 30, 2023 | 4.56 Mn |
| Mar 31, 2023 | 4.19 Mn |
| Dec 31, 2022 | 5.81 Mn |
| Sep 30, 2022 | 6.15 Mn |
| Jun 30, 2022 | 5.88 Mn |
| Mar 31, 2022 | 5.28 Mn |
| Dec 31, 2021 | 3.95 Mn |
| Sep 30, 2021 | 3.33 Mn |